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Abstract
Suicide is a major cause of death among patients with schizophrenia. Research indicates that at least 5–13% of
schizophrenic patients die by suicide, and it is likely that the higher end of range is the most accurate estimate. There is
almost total agreement that the schizophrenic patient who is more likely to commit suicide is young, male, white and
never married, with good premorbid function, post-psychotic depression and a history of substance abuse and suicide
attempts. Hopelessness, social isolation, hospitalization, deteriorating health after a high level of premorbid functioning,
recent loss or rejection, limited external support, and family stress or instability are risk factors for suicide in patients
with schizophrenia. Suicidal schizophrenics usually fear further mental deterioration, and they experience either
excessive treatment dependence or loss of faith in treatment. Awareness of illness has been reported as a major issue
among suicidal schizophrenic patients, yet some researchers argue that insight into the illness does not increase suicide
risk. Protective factors play also an important role in assessing suicide risk and should also be carefully evaluated. The
neurobiological perspective offers a new approach for understanding self-destructive behavior among patients with
schizophrenia and may improve the accuracy of screening schizophrenics for suicide. Although, there is general
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consensus on the risk factors, accurate knowledge as well as early recognition of patients at risk is still lacking in everyday
clinical practice. Better knowledge may help clinicians and caretakers to implement preventive measures.
This review paper is the results of a joint effort between researchers in the field of suicide in schizophrenia. Each expert
provided a brief essay on one specific aspect of the problem. This is the first attempt to present a consensus report as
well as the development of a set of guidelines for reducing suicide risk among schizophenia patients.
I. Background
Despite great efforts, suicide rates among schizophrenic
patients remain alarmingly high. A comprehensive analy-
sis recently appeared [1], and a number of opinion leaders
have been involved in the develpment of books, papers
and conferences to understand and prevent suicidal
behavior in patients suffering from schizophrenia [1].
This paper is one such effort. It presents a review of the
many aspects of suicidal behavior in schizophrenia and
attempts to develop and share guidelines for the preven-
tion of suicide in schizophrenics.
In 1977, Miles [2] reviewed 34 studies of suicide among
schizophrenics and estimated that 10% of schizophrenic
patients kill themselves. Follow-up studies have estimated
that 10–13% of individuals with schizophrenia die by sui-
cide, which is the main cause of death among these
patients [3]. However, a recent meta-analysis estimated
that 4.9% of schizophrenics commit suicide during their
lifetime [4]. This percentage surprised many researchers as
it was lower than previously thought. Regardless, it is still
an unacceptably high incidence. Inskip, et al. [5] per-
formed a meta-analysis on suicide among patients with
affective disorder, alcoholism and schizophrenia and esti-
mated that the lifetime risk of suicide was 6% for affective
disorder, 7% for alcohol dependence and 4% for schizo-
phrenia, an estimate which is consistent with Palmer's
estimate. They concluded, therefore, that the lifetime sui-
cide risk figure of 10% or more appears to be too high,
although Meltzer [6] disagrees. Following an index suicide
attempt, mortality from suicide in schizophrenia patients
may be as high as 1% per year for the next five years [7,8].
Pompili, et al. [9] reviewed the literature on suicide
among inpatients with schizophrenia and found that the
suicide rate in cohorts of schizophrenic patients who were
followed-up after the first hospitalization for periods
ranging from 1 to 26 years was 6.8%.
Harris and Barraclough [10] included 28 studies in their
meta-analysis and found that the risk of suicide among
patients diagnosed with schizophrenia exceeded that in
the general population more than eight fold [SMR = 8.45,
CI = 7.98–8.95]. Brown [11] found that schizophrenia
was associated with excess death from both natural causes
(e.g., respiratory diseases) and unnatural causes (acci-
dents, suicide, and homicide). Suicide accounted for 12%
of all deaths among schizophrenia patients and about
28% of all excess deaths. According to Brown, the excess
mortality was highest in first episode or early illness phase
patients, indicating a high rate of suicide early in the ill-
ness. Danish studies that assessed standard mortality
ratios (SMR) in successive national cohorts suggest that
the SMR may be rising in first-episode schizophrenia in
Denmark [12] and falling in chronic schizophrenia [13].
At the same time, other data indicate that suicide risk may
be elevated across the entire course of schizophrenia. A
recent examination of the suicides of all patients with
schizophrenia in Finland over a 12-month period found
that fully one-third of the schizophrenic suicides were
over the age of 45 [14]. Despite great efforts, both on the
side of drug treatment and psychosocial strategies, the
number of suicides among schizophrenic patients has
remained unchanged [15], although Nordentoft et al. [16]
have shown that suicide among Danish patients with
schizophrenia has fallen, paralleling the reduction of sui-
cide in the general population.
Suicide attempts, which often result in death from suicide
at a later time, are common among patients with schizo-
phrenia; about 20–40% of these patients do make suicide
attempts [17-19].
Many factors associated with suicide in schizophrenia
have been identified, but attempts to identify high-risk
patients have so far produced too many false positive
results to be clinically useful [3]. Yet, identification of risk
factors is a major tactic for predicting and preventing sui-
cide. This review is based on systematic search of the inter-
national literature as well as on the experience of scholars
who are dedicated researchers in the field. Opinion lead-
ers in this field agreed to provide a summary of the state
of the art for specific aspects of the problem. This paper
therefore represents the first attempt to combine the
efforts of researchers into suicide in schizophrenia in
order to improve the understanding of the problem.
II. Materials and methods
We conducted careful MedLine, Excerpta Medica, and Psy-
cLit searches to identify papers and book chapters in Eng-
lish during the period 1966–2006. We also performed
Index Medicus and Excerpta Medica searches prior to
1966. Search terms were "suicid*" (which comprises sui-
cide, suicidal, suicidality, and other suicide-related
terms), "parasuicid*," "schizophren*," "inpatient or in-Annals of General Psychiatry 2007, 6:10 http://www.annals-general-psychiatry.com/content/6/1/10
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patient", and "outpatient". Each term was also cross-refer-
enced with the others using the MeSH method (Medical
Subjects Headings). Using the same databases and meth-
ods, we also crossed-referenced the above-mentioned
terms with key words such as "neurocognition" or "neuro-
cognitive," "neuroleptics or antipsychotics" (all terms
belonging to the neuroleptics or to the antipsychotics cat-
egories were checked).
In this way, the entire literature on suicide in schizophre-
nia was carefully reviewed. By reviewing selected articles
we identified some specific fields of interest. Sources of
information also included original epidemiological
research by the authors as well as classifications and data
from World Health Organization. The authors agreed on
a number of key topics relevant to the aim of this paper.
III. Results
1. Risk factors
There is almost total agreement that the schizophrenic
patient who is more likely to commit suicide is young,
male, white, and never married, with good premorbid
function, post-psychotic depression and a history of sub-
stance abuse and suicide attempts. Hopelessness, social
isolation, hospitalization, deteriorating health with a high
level of premorbid functioning, recent loss or rejection,
limited external support, and family stress or instability
are important risk factors in schizophrenic individuals
who commit suicide. These patients usually fear further
mental deterioration, and they show either excessive treat-
ment dependence or loss of faith in treatment. Awareness
of the illness has been reported as a major risk factor
among schizophrenic patients who at risk of suicide. Pro-
tective factors also play an important role for assessing
suicide risk and, therefore, should be carefully evaluated.
Although there is a general consensus on these factors,
proper knowledge and, therefore, early recognition of
patients at risk is still lacking in everyday clinical practice.
Fenton et al. [20] and Fenton [21] described the high risk
patient as a young male, with a history of good adolescent
functioning and high aspirations, late age of first hospital-
ization, higher IQ, with a paranoid or non-deficit form of
schizophrenia, who retains the capacity for abstract think-
ing and who may be painfully aware of the impact of a
deteriorating illness on his aspirations and life trajectory.
Risk factors for schizophrenia are summarized in Figure 1
and Table 1.
Positive symptoms are generally less often included
among risk factors for suicide in schizophrenia. However,
a number of studies have found that the active and exac-
erbated phase of the illness and the presence of psychotic
symptoms [14,22-24], as well as paranoid delusions and
thought disorder [25,26], are associated with a high risk of
suicide. Patients with the paranoid subtype of schizophre-
nia are also more likely to commit suicide [27,20]. Sui-
cides as a result of command hallucinations, although
rare, have been reported in the literature [28]. Kelly, et al
[29] reported that a large proportion of their schizo-
phrenic patients who committed suicide had poor control
of thoughts or thought insertion, loose associations and
flight of ideas as compared to those who died by other
means of death.
A recent systematic review of risk factors for schizophrenia
and suicide [30] identified 29 relevant studies and 7
robust risk factors including previous depressive disorder
(OR = 3.03, 95% CI = 2.06–4.46), previous suicide
attempts (OR = 4.09, 95%CI = 2.79–6.01), drug misuse
(OR = 3.21, 95%CI = 1.99–5.17), agitation or motor rest-
lessness (OR = 2.61, 95%CI = 1.54–4.41), fear of mental
disintegration (OR = 12.1, 95%CI = 1.89–81.3), poor
treatment adherence (OR = 3.75, 95%CI = 2.20–6.37),
and recent loss (OR = 4.03, 95%CI = 1.37–11.8). A
reduced risk of suicide was associated with hallucinations
(OR = 0.50, 95%CI = 0.35–0.71. The authors argued that
command hallucinations were not an independent risk
factor, but they increased the risk in those already predis-
posed to suicide. Overall, suicide was less associated with
the core symptoms of psychosis and more with affective
symptoms, agitation, and awareness that the illness was
affecting mental function.
The neurobiological perspective offers a new approach for
understadinding self-destructive behavior among patients
with schizophrenia and provides a basis for screening pro-
grams other than using the risk factors that are usually part
of the clinical assessment. Low concentrations of the sero-
tonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) in
the cerebrospinal fluid (CSF) are associated with suicidal
behavior in patients with depressive illness and with
schizophrenia. In a prospective study, Cooper et al. [31]
measured 5-HIAA in the CSF taken from 30 schizophrenic
patients in a drug-free state and followed these patients
for 11 years. Ten patients made suicide attempts during
the follow-up period. The suicide attempters had signifi-
cantly lower concentrations of CSF 5-HIAA at initial eval-
uation than the non-attempters. These findings provided
evidence for an association between serotonergic function
and suicide and suggested a role in schizophrenia for
drugs with serotonergic effects. Hormones known to be
under serotonergic control, such as prolactin (PRL), can
be measured in peripheral blood after stimulation or inhi-
bition of the serotonergic (5-HT) receptors. Fenfluramine
(FEN) is a widely used serotonin probe. In humans, D-
fenfluramine (D-FEN), given orally, results in an increase
in plasma PRL level, which is considered to be a higly spe-
cific test of serotonergic function [32]. It has been demon-
strated that a blunted PRL secretion in response to D-FENAnnals of General Psychiatry 2007, 6:10 http://www.annals-general-psychiatry.com/content/6/1/10
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is associated with suicidal behavior in schizophrenic
patients [33]. This is an important tool since this tech-
nique gives a specific indication of serotonergic function,
and it can be combined with new neuroimaging para-
digms such as PET and SPECT, providing images of
seronergic function in vivo [34-37].
Plocka-Lewandowska et al. [37] found an association
between results of the dexamethasone suppression test
(DST) and suicide attempts in schizophrenic patients,
suggesting a possible association between a hyperactive
hypothalamo-pituitary-adrenal (HPA) axis and suicidal
behavior in schizophrenic patients. Jones et al. [39] found
that nonsuppression in the DST was associated with sui-
cidal behavior in a sample of schizophrenic patients, and
non-suppression of the DST differentiated suicide
attempters from non-attempters. Reports of an associa-
tion between both REM sleep abnormalities and the
results of the DST and suicidal behavior in schizophrenia
have been reported [38,39]. Keshavan et al. [38] found
that those schizophrenic patients who exhibited suicidal
behavior had increased overall REM activity and REM
time. Lewis et al. [40] contradicted these findings and
reported that, in their sample of schizophrenic patients,
total REM sleep time was associated with suicidal behav-
ior. These authors suggested that, since serotonergic func-
tions act to suppress REM sleep, reduced serotonergic
function in schizophrenia could explain the association
between suicidal behavior and REM time/activity
observed by other authors. Hinse-Selch et al. [41] investi-
gated the effects of clozapine on sleep in a sample of schiz-
ophrenic patients and found a significant clozapine-
induced increased in non-REM sleep in patients who do
not experience clozapine-induced fever; while the
amounts of stage 4 and slow-wave sleep decreased signif-
icantly. These findings might explane the anti-suicidal
role of clozapine since increasing REM sleep has been cor-
related with increased suicide risk.
A summary of risk factors for suicide in schizophrenia Figure 1
A summary of risk factors for suicide in schizophrenia.Annals of General Psychiatry 2007, 6:10 http://www.annals-general-psychiatry.com/content/6/1/10
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a. Suicide attempts
Compared with suicide attempts among persons without
schizophrenia, attempts among those with schizophrenia
are serious and typically require medical attention. Sui-
cidal intent is generally strong, and the majority of those
who attempt suicide have made multiple attempts. In
addition, the methods used to attempt suicide are consid-
ered more lethal than those used by suicidal persons in
the general population. Gupta and colleagues [42]
reported that, in their sample of patients with schizophre-
nia, suicide attempts were associated with the number of
lifetime depressive episodes, and depression has been rec-
ognized as a major risk factor among persons with schiz-
ophrenia who have attempted suicide. Roy and associates
[43] found that significantly more of their sample of
patients with schizophrenia who had attempted suicide
had suffered from a major depressive episode at some
time during their illness.
In contrast, Drake et al. [44] found, in their sample of
schizophrenic patients, that those who had attempted sui-
cide were trying to manipulate others, consolidate sup-
port or gain entrance to the hospital. Attempts frequently
occurred in the context of interpersonal conflict, such as
arguments with family or housemates. These authors sug-
gested that impulsive attempts were associated with the
dysphoric side-effects of the medication, such as akathisia.
Nevertheless, in a recent study, akathisia was not linked to
suicidality or depression among patients with treatment-
resistant schizophrenia [45].
In a study [46] comprising 500 patients affected with
schizophrenia and/or affective disorders, a history of sui-
cide attempts was associated with comorbidity, low scores
on the Global Assessment Scale (GAS), low age at onset
and poor premorbid adjustment. This study showed that
men affected with schizophrenia were less likely to
attempt suicide when compared to men with diagnoses
Table 1: Risk factors for suicide in schizophrenic outpatients and inpatients (modified from [9])
White, young, male (often under 30 years)
Unmarried
High premorbid expectations
Gradual onset of illness
Social isolation
Fear of further mental deterioration
Excessive treatment dependency
Loss of faith in treatment
Family stress or instability
Limited external support
Recent loss or rejection
Hopelessness
Deteriorating health
Paranoid schizophrenia
Substance abuse
Deliberate self-harm
Unemployement
Chronicity of illness with numerous exacerbation
Family history of suicide
Pre-admission and intra-admission suicidal attempts
Agitation and impulsivity
Fluctuating suicidal ideation
Extrapiramidal symptoms caused by medications
Prescription of a greater number of neuroleptic and antidepressants
Increased length of stay, increased number of ward changes, discharge planning and period following discharge
Period of approved leave
Apparent improvement
Past and present history of depression
Frequent relapses and rehospitalization
Longer hospitalization periods than other psychiatric inpatients
Negative attitudes towards medication and reduced compliance with therapy
Living alone before the past admission
Charged feelings about their illness and hospital admission
Early signs of a disturbed psychosocial adjustment
Dependence and incapability of working
Difficult relationship with staff and difficult acclimation in ward environment
Hospitalization close to crucial sites (big roads, railway stations, rivers, etc).Annals of General Psychiatry 2007, 6:10 http://www.annals-general-psychiatry.com/content/6/1/10
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other than schizophrenia. Among women, suicide
attempts were more common in those with lower age at
onset and who had no children. Kelly et al. [29] found
that, among their sample of schizophrenia patients who
had committed suicide, some 93% had engaged in previ-
ous suicidal behaviors versus only 23% of the patients
who died by other means of death.
Suicide attempts are a significant risk factor for suicide
and are associated with significant medical costs and, for
this reason, an examination of risk factors for attempted
suicide in schizophrenia is important. A recent systematic
review of the risk factors for attempted suicide in schizo-
phrenia identified only 14 studies that met selection crite-
ria [47]. These authors examined 29 variables that were
studied in at least two or more studies and found only five
significant variables: past suicidal ideation, previous
deliberate self harm, previous depressive episodes, drug
abuse or dependence, and a higher mean number of psy-
chiatric admissions
Great caution is required during the period after hospital
discharge because patients with schizophrenia usually
experience hopelessness and demoralization during this
time. For these patients, discharge often means losing the
hospital environment and the people who in some way
have become central in their life. The number of psychiat-
ric admissions, which are usually higher among patients
who have attempted suicide, may be indicative of a severe
relapsing illness.
b. Insight and suicide risk
The concept of insight has always been an important part
of clinical psychiatry and neuropsychiatry nomenclature
but, until recently, the term had been used to describe a
disparate and wide range of phenomena [48]. During the
last fifteen years, most researchers have defined insight as
being comprised of at least three domains: awareness of
the illness, awareness of the need for treatment, and
awareness of the consequences of the disorder [49].
Increased agreement on terminology and phenomenol-
ogy and the development of reliable and valid measures
of insight has led to an explosion of research in this area.
The relationship between insight and suicide has been an
area of study that has benefited.
Many scholars and clinicians have proposed a relation-
ship between insight and suicidal behavior in patients
with psychotic disorders. Early empirical studies on the
predictors of suicidal behavior in patients with psychotic
disorders often noted the consequences of a fuller under-
standing of the implications of having a psychotic disor-
der, and the sense of resignation and hopelessness that
was often associated with this awareness. Studies by Far-
berow, Shneidman and Leonard [50], Warnes [51], and a
series of studies by Drake and colleagues in the 1980's
[52-55] all reported very similar findings and cited a
hopeless awareness of the severity of their psychopathol-
ogy as one of the most important predictors of completed
suicide in patients with psychotic disorders. While these
studies suggested increased awareness of one's illness was
associated with suicidal behavior in these patients, it was
not possible to determine whether insight was directly
related to suicide or only indirectly related via its influ-
ence on hopelessness. In addition, because these studies
predated advances in research methodology, poor relia-
bility for the measurement of insight contributed to the
ambiguity of the results. With the development of reliable
and valid measures for the assessment of insight [56-58],
more recent research has been able to clarify these rela-
tionships.
Two recent studies studied the relationship between
insight and suicide while taking hopelessness into
account. In the first study, Kim et al. [59] compared two
groups of patients with schizophrenia: 200 with a lifetime
history of suicidal ideation and/or attempts and 133 with-
out any history of suicidality. The group with a history of
suicidality had significantly higher levels of both general
awareness of illness and hopelessness. However, when
hopelessness and insight were entered into a multiple
regression model, along with several other variables, only
hopelessness was statistically significant. In the second
study, Bourgeois and colleagues [60] analyzed data from
980 patients from the International Suicide Prevention
Trial (InterSePT) [61]. The results were similar to those of
Kim et al. [59]. Greater awareness of illness significantly
predicted suicide risk when entered independently into
the model (with better insight associated with increased
suicide risk), but was no longer significant once hopeless-
ness was entered into the equation. Interestingly, the base-
line level of awareness was associated with increased risk
for suicidal behavior, but improvement in awareness over
the follow-up period was associated with reduced risk for
suicidal behavior. In summary, research to date suggests
that awareness of illness is indeed associated with
increased suicide risk in this population, but only if that
awareness leads to hopelessness. This conclusion is con-
sistent with the literature demonstrating the relationship
between hopelessness and suicide [62-64] and helps to
reconcile those research findings with the positive prog-
nostic implications of improvement in awareness of the
illness [65]. The severity of the hopelessness that a person
with schizophrenia experiences seems contingent, at least
in part, on the level of premorbid functioning and the
magnitude of the decline in functioning relative to that
premorbid capacity.
Several points can be made about the clinical implications
of these findings. Patients with schizophrenia need to beAnnals of General Psychiatry 2007, 6:10 http://www.annals-general-psychiatry.com/content/6/1/10
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carefully assessed for hopelessness and suicidal ideation
throughout the course of their illness, particularly if there
is marked improvement their in awareness of any facet of
the illness syndrome. In addition, although improve-
ments in insight are often strongly related to improve-
ments on many clinical dimensions, we must work
judiciously when we strive to increase insight in patients
with other risk factors, such as young age and a substantial
decline from the premorbid level of functioning. There is
often a mourning process that individuals diagnosed with
schizophrenia must pass through as they come to terms
with what was lost with the onset of their illness, with the
magnitude of the loss being determined by many factors
[66]. By being attentive to this process, we can better
assess the relative risk for our patients on an individual on
a case-by-case basis.
c. Depression and hopelessness
Depression, as a mood or a syndrome, is frequently
present in people with schizophrenia, and yet depression
is also frequently under-diagnosed and under-treated.
Depression is considered to be a major risk factor for sui-
cidal behavior across populations. Researchers have sug-
gested that depression can serve as a stressor or trigger for
suicidal behavior among individuals who are at risk for
suicidal behavior [67], and this has been demonstrated
among individuals with schizophrenia [68]. For example,
Harkavy-Friedman and colleagues [68,69] demonstrated
that major depression serves as a trigger for suicide
attempts, and depressed mood and hopelessness are cor-
related with current suicidal ideation.
Many researchers have found high rates of major depres-
sive disorder among individuals with schizophrenia
[54,55,69-72], and it is a requirement for the diagnosis of
schizoaffective disorder in the DSM-IV [73]. In addition,
many researchers have identified depressed mood and
hopelessness as an important component of suicidal
behavior [53,74-76]. Despite this knowledge, depression
is often ignored and untreated among individuals with
schizophrenia, leading to increased risk for suicidal
behavior. It has been demonstrated that antidepressants
can be used effectively for treating depression without
increasing psychotic symptoms [77,78], but they are still
under-utilized in this at-risk population.
While depression can often be masked or confused with
the negative symptoms or side-effects of medication
[79,80], an astute clinician can identify depression by ask-
ing targeted questions. While not all suicide attempts and
completed suicides in schizophrenia are triggered by
depression, psychological and psychopharmacological
treatment of depression is likely to play an important role
in preventing suicidal behavior in schizophrenia.
Adequate attention to depression, in the form of assess-
ment and treatment, as well as consideration of other fac-
tors that may trigger suicidal behavior in schizophrenia, is
important. Ongoing clinical assessment for the signs and
symptoms of depression is essential. When identified,
depression must be treated, and psychopharmacological,
as well as cognitive-behavioral and psychosocial interven-
tions, ought to be considered.
The depression-related aspects of schizophrenia are gener-
ally differentiated according to the time at which they
occur during the psychotic episodes – contemporaneously
with the psychosis or as a "post-psychotic depression"
phenomenon. This latter syndrome has been reported as
particularly relevant for suicide risk [81,82].
In general, for a variety of populations, both normal and
disturbed, the most powerful predictor of suicidality, both
completed suicide and attempted suicide, is depression,
both the psychiatric diagnosis (major depressive disorder
or biopolar disorder) and the mood as assessed by clinical
judgment or by self-report inventories [83]. Beck et al.
[84] found that the cognitive component of depression,
which they first called pessimism and later hopelessness,
was a more powerful predictor of subsequent suicide than
the more general syndrome of depression. For example, in
a follow-up study of psychiatric outpatients, Beck and his
colleagues [85] found that hopelessness scores were sig-
nificantly related to subsequent completed suicide.
Nordentoft et al. [86] studied patients with first-episode
schizophrenia-spectrum disorders for one year, during
which time 11% attempted suicide. Suicidal ideation and
plans in the prior year were predicted by hopelessness
scores, while actual suicide attempts in the prior year were
predicted by both depression and hopelessness scores.
Drake and Cotton [87] compared 15 schizophrenic inpa-
tients who completed suicide subsequently with schizo-
phrenics who did not do so during a 3 to 7 year follow-up.
The suicides were judged to be more hopeless but not
more depressed. Schizophrenics with depressed mood
had a probability of 0.22 of subsequently completing sui-
cide while schizophrenics with depressed mood and
hopelessness had a 0.37 probability of doing so. A
depressed mood alone resulted in a 0.07 probability of
subsequent completed suicide and no depressed mood
(with or without hopelessness) a 0.06 probability. It
appears, then, that hopelessness was an important factor
in predicting suicide.
Hopelessness plays a larger role in schizophrenia than its
association with suicidality. For example, Aguilar et al.
[88] observed that first-episode schizophrenic patients
had higher levels of hopelessness (as measured by Beck's
hopelessness scale) than other non-affective psychotics.Annals of General Psychiatry 2007, 6:10 http://www.annals-general-psychiatry.com/content/6/1/10
Page 8 of 22
(page number not for citation purposes)
Furthermore, higher hopelessness scores predicted a
worse short-term outcome, in particular, worse global
functioning at a one-year follow-up. (Depression scores
did not predict outcome.)
Some investigators have drawn attention to the role of
insight or awareness of their disorder (and its progres-
sion) as affecting the level of hopelessness and suicidality
in schizophrenics. For example, Strauss [89] interviewed
schizophrenics about the course of their disorder, and he
noted that a relapse after gradual improvement can lead to
extreme despair in patients. It appears also that insight
into their disorder appears to increase the level of hope-
lessness in schizophrenics and increases their risk of sui-
cide, whereas neurocognitive deficits that impede
awareness reduce the risk of suicide.
d. Symptoms and subtype
Are there clinical symptoms or illness subtypes that are
associated with suicide and that could serve as indicators
of suicidal danger? Some symptoms are generally indica-
tive of suicidal danger regardless of the diagnosis. Depres-
sive symptoms have already been addressed, but they
frequently coexist with anxiety symptoms [90,91]. Anxiety
contributes to suicidality in post-psychotic depression
[92], and comorbidity with panic attacks was associated
with higher suicide rates in patients with schizophrenia
[93]. Suicide was correlated with psychomotor agitation
and restlessness [30,94] and a fear of mental disintegra-
tion, if present, predicts suicide with an odds ratio of 12.1
[30]. Akathisia is manifested subjectively in an unbearable
feeling of inner tension and restlessness, and subjective
awareness of akathisia is also associated with higher suici-
dality. Findings from a study devoted to this topic demon-
strated that, among patients with akathisia, there was a
greater likehood of suicidal behavior than among those
without akathisia [95]. These authors stressed that their
findings imply that the suicidality may be related to inter-
nal feelings of distress that are concomitantly expressed
both as subjective restlessness and as hopelessness and
suicidal ideation. Akathisia is also associated with a con-
stellation of symptoms with both affective and anxious
features as well as motor components.
In addition to general risk factors, there may also be risk
factors more or less characteristic for patients of a particu-
lar diagnostic group. Are there specific characteristics of
the schizophrenic disorder associated with or predispos-
ing to suicide? Separate sections of this review are devoted
to the role of positive symptoms, negative symptoms,
command hallucinations and insight. According to Zil-
boorg [96], clinical evidence for strong hostility can be
found in every suicide, and aggressiveness, impulsivity
and non-compliance are particularly frequent in schizo-
phrenic illness. These characteristics help to differentiate
between suicidal and non-suicidal schizophrenia patients
[97]. Hostility at admission was associated with long-term
suicide risk [21], and involvement of the police at the time
of admission seems to be a specific risk factor within the
schizophrenia population not encountered elsewhere
[98]. However, it is perhaps impulsivity rather than
aggressiveness that may be of importance. Suicidal sub-
jects were found to exhibit acting-out behavior, to run
away from hospital and to be more often discharged
against medical advice [24]. Many suicide victims experi-
enced compulsory hospital treatment, and the majority of
them had poor treatment adherence [24,99].
The importance of psychopathology for suicidal behavior
may change over time. Considering the condition of the
patient immediately before suicide, no uniform picture
could be identified. A withdrawal from relationships due
to depression has been described, as has an increase in the
patient's paranoid behavior, and both should be regarded
as acute signals of suicidal danger [25]. Farberow et al.
[100] described presuicidal schizophrenic patients as
extremely tense, restless and impulsive. Such patients can
suddenly become quiet and calm at the time the decision
to commit suicide is made. A comprehensive account of
the psychopathological conditions preceding suicide has
been provided by Wolfersdorf et al. [101]. In comparison
to schizophrenic controls, suicides had a higher degree of
subjective suffering and ambivalence, and most of them
were preoccupied by the feeling of having failed. Accord-
ing to Drake et al. [102], the patients' presuicidal condi-
tion is characterized by feelings of inadequacy,
hopelessness and fears of mental disintegration. Also, the
patients tend to develop a more negative or indifferent
attitude towards the psychiatric personnel, and they often
no longer request support or attention [103].
Schizophrenia is an illness of considerable heterogeneity,
and several attempts have been made to differentiate sub-
types. Regarding suicide, classical subtypes of paranoid,
catatonic, hebephrenic, and undifferentiated schizophre-
nia do not seem to be of importance [94,104]. Andreasen
and Olsen [105] proposed differentiation into positive,
negative and mixed schizophrenia. There is some evi-
dence for a weak negative correlation between positive
symptoms, and thus positive schizophrenia, and suicide
[30]. Another typology has been devised by Crow [106]
who differentiated the type I schizophrenia syndrome,
equivalent to acute schizophrenia, and type II, equivalent
to the defect state. Both an early onset of a defect state [24]
and the deficit subtype of the illness [20,21] were associ-
ated with a reduced risk of future suicide. Nevertheless, it
is not the specific syndrome, but the course of the illness,
frequent relapses [24,101], a high severity of illness, a
downward shift in social and vocational functioning
[21,107,108], and a realistic awareness of the deteriora-Annals of General Psychiatry 2007, 6:10 http://www.annals-general-psychiatry.com/content/6/1/10
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tive effect of the illness that are the schizophrenia-specific
suicide risk factors [3].
There are many ways to classify suicidal patients, and
many of these typologies are also applicable to patients
with schizophrenia. For instance, a differential typology
has been proposed with respect to the "hard" and "soft"
suicidal method [109], an ethical typology based on the
role a clinician may play in the suicidal process [110], and
a sociological typology reflecting the societal level of
social integration and moral regulation [111]. The clinical
usefulness of all these typologies for predicting suicide
seems to be limited, however, and the same applies to the
differentiation between single suicides, extended suicides
and suicidal pacts. Both latter types are extremely rare in
patients with schizophrenia.
About one third of suicide victims are found to meet the
criteria for a personality disorder [112], and a classifica-
tion using the presence or absence of Axis II disorders
would be feasible. Nevertheless, this variable seems to
play a less important role in schizophrenia due to its less
frequent comorbidity with schizophrenia. In contrast,
comorbidity of schizophrenic and substance use disorders
is very frequent [113], and a typology based on the addi-
tional presence or absence of an addictive disorder could
be meaningful, the more so as drug misuse or dependence
considerably increases the risk of suicide [30].
Some other suicide subtypes have been described in schiz-
ophrenic disorders, but they have been only clinically
inferred and not empirically tested. Based on their study
of psychotic inpatients and their behavior in the psychiat-
ric hospital setting, Farberow et al. [100] proposed three
subtypes of schizophrenic suicide: (1) the unaccepting,
grossly disturbed patient resisting hospitalization; (2) the
dependent, satisfied patient whose suicide outside the
hospital appears to be a consequence of stressful conflict
and ambivalence concerning the home environment; and
(3) the dependent, dissatisfied, demanding patient who
has no other place to go and yet seems to have lost faith
in the therapeutic potential of hospitalization. In an
investigation on suicide [114], the authors learned to dif-
ferentiate two other clinical types of schizophrenic sui-
cide: (1) Type I schizophrenia suicide, characterized by
early illness onset along with early difficulties in psycho-
social adaptation, and (2) Type II characterized by a later
illness onset where the patients often show a high premor-
bid functional capacity. However, due to the seriousness
of their illness, they experience a distinct psychosocial and
professional downward mobility. Patients of both types
have insight with regard to their condition and are capa-
ble of critical and realistic self-assessment of their reduced
life perspectives [115]. Their suicide occurs in a non-psy-
chotic condition. Type I patients realize their failure in
comparison with the achievements of their peers, while
Type II patients are not able to live up to their high expec-
tations and feel inadequate in relation to their own goals
[102]. In both types, suicide appears to be the result of a
realistic appraisal of the patients' whole life situation
including the incapacitating illness and its negative psy-
chosocial consequences.
Positive and Negative Symptoms as Suicide Risk Factors in 
Schizophrenia and other Psychiatric Disorders
The relationship between suicide and psychiatric disor-
ders has remained an important question over the past
three decades in psychiatry and psychology. A number of
classic studies have attempted to connect suicide to a gen-
eral history of mental illness and to the specific diagnoses
of depression, alcoholism, schizophrenia, and organic
psychoses [116-119]. However, as Hendin [120] pointed
out, "the vast majority of depressed, schizophrenic, alco-
holic or organically psychotic patients do not commit or
even attempt suicide." Hendin went on to suggest that
"the interest in classifying populations of suicidal patients
by their psychiatric diagnoses is being supplemented by
an interest in understanding what makes a minority of
patients within any given diagnostic category suicidal
while the majority are not suicidal."
The search for suicide risk factors independent of diagno-
sis has been espoused by a number of researchers and cli-
nicians representing several different points of views.
Weismann et al. [121], for example, suggested that sui-
cidal patients exhibited greater hostility than did
depressed patients. Beck and his colleagues [76,122]
found that hopelessness was a stronger predictor of sui-
cide than the degree of depression. Fawcett et al. [71]
argued that different risk profiles may emerge for different
diagnoses.
The differentiation of positive and negative symptoms has
become a key factor in understanding psychiatric disor-
ders and the potential differences between various types
of psychiatric disorders. Positive symptoms refer to fla-
grant reality distortions such as psychosis (e.g., delusions
and/or hallucinations) and disorganization/formal
thought disorder. Negative symptoms refer to symptoms
such as poverty of speech and flat affect. A third type of
symptom grouping involves neurocognitive disorders or
cognitive deficits (e.g., concrete thinking and slow
processing speed).
The distinction between positive and negative symptoms
was made originally by Hughlings Jackson [123]. Kraepe-
lin's [124] seminal formulation viewed the disorder that
we now label as "schizophrenia" as an early-onset demen-
tia marked by a deteriorating clinical course. Although
Kraepelin [124] emphasized both positive and negativeAnnals of General Psychiatry 2007, 6:10 http://www.annals-general-psychiatry.com/content/6/1/10
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symptoms, the attention of both researchers and clini-
cians was drawn to the most flagrant and dramatic posi-
tive symptoms – hallucinations, delusions and
disorganization/formal thought disorder – as the princi-
pal components of schizophrenia [125]. In the last three
decades, there has been renewed interest by investigators
in the distinction between positive and negative symp-
toms [126-131], and specifically in the examination of the
more stable negative symptoms associated with schizo-
phrenia such as poverty of speech and flat affect. There has
also been increased interest in neurocognitive impairment
or cognitive deficit symptoms such as slow processing
speed and concrete thinking [132].
There have been a few studies exploring the relationship
between positive symptoms and suicidal activity. For
example, there is strong evidence that psychotic episodes
precipitate suicide attempts (and homicide) in some
schizophrenic persons [133,134]. Several interesting stud-
ies have explored the relationship between type of delu-
sional content and serious suicide attempts [135,136].
There have been fewer studies on the relationship
between negative symptoms and suicide. For example,
Fawcett et al. [137] found a relationship between anhedo-
nia and committing suicide within one year.
Two recent studies by Kaplan and Harrow [138,139] and
a review article by Kaplan et al. [140] have explored the
relationship of positive symptoms, negative symptoms,
cognitive deficits and overall post-hospital functioning to
subsequent suicidal behavior at a two-year follow-up of
psychiatric patients. The sample of 203 patients from the
Chicago Follow-up Study included 71 patients with schiz-
ophrenia, 35 with a schizoaffective disorder and 97 with
non-psychotic depression. The results supported a multi-
factor model of suicide risk. Some risk factors held across
diagnosis (e.g., poor early functioning) while others were
diagnostic-specific: Early psychosis predicted later suicidal
activity for both schizophrenia and schizoaffective
patients but not for depressives, and some negative symp-
toms predicted later suicidal activity for schizoaffective
patients while some cognitive deficits predicted later sui-
cidal activity for non-psychotic depressives. The effects of
psychosis were almost totally mediated through the level
of functioning for the schizophrenia patients but not for
the schizoaffective patients, for whom psychosis directly
affected later suicidality independently of the effects of
poor functioning.
The results of this study begin to establish a tentative basis
for a disease-based approach to suicide prevention. A sui-
cide prevention approach for schizophrenia patients
should center on improving their over all functioning and
decreasing their general discouragement and hopeless-
ness. Treatment for the schizoaffective patients in contrast
should focus additionally on the reduction of psychosis
per se in addition to the reduction of negative symptoms.
For non-psychotic depressive patients, the reduction of
cognitive deficits may be especially important in prevent-
ing later suicidal activity independent of the improvement
in overall functioning. Clinicians should consider assess-
ing hopelessness and demoralization in all diagnostic
groups to help evaluate potential suicidal risk activity.
Command hallucinations
Command hallucinations, wherein patients hear voices
explicitly instructing them to engage in specific acts [141],
are more common among those with schizophrenia-spec-
trum disorders than is often recognized, occurring in 18–
50% of that population [28,142]. Often these command
hallucinations are suicidal in nature, thereby placing indi-
viduals who are vulnerable to suicide at even greater risk.
However, there are few empirical studies in this area, and
their results are conflicting as to the legitimacy of com-
mand hallucinations as a consistent risk factor in suicide
or violence toward others. Hellerstein et al. [141] con-
ducted one of the first controlled studies investigating the
relevance of command hallucinations in suicidal behavior
or violence. Comparing patients with and without com-
mand hallucinations yielded no significant differences in
rates of suicidal or assaultive acts. More broadly, patients
with hallucinations (regardless of type) were just as likely
to report suicidal ideation as those not experiencing hal-
lucinations. Zisook et al. [28] similarly reported that
patients with command hallucinations and those without
command hallucinations did not differ on number of
prior suicide attempts, nor on a history of violent/impul-
sive acts. A literature review by Rudnick [143] also showed
a lack of a relationship between command hallucinations
and violence toward self or others. More recently,
Harkavy-Friedman et al. [120] sampled 100 inpatients
with schizophrenia or schizoaffective disorder, divided
between those who had experienced command auditory
hallucinations (n = 22) and those who had not (n = 78).
The rate of suicide attempts did not differ significantly
between the two groups.
On the other hand, Rogers et al. [144] compared 56 foren-
sic patients with a lifetime history of command hallucina-
tions with 54 non-command hallucinators. The presence
of self-injurious command hallucinations was a signifi-
cant predictor of self-harming behavior, although this
study was not restricted to schizophrenic patients. Fur-
thermore, Nordentoft et al. [84] reported that hallucina-
tions were one of only two significant variables predicting
attempted suicide in a randomized controlled trial of inte-
grated treatment for patients with schizophrenia-spec-
trum disorders.Annals of General Psychiatry 2007, 6:10 http://www.annals-general-psychiatry.com/content/6/1/10
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The aforementioned study results indicate that the prog-
nostic significance of command hallucinations is unre-
solved. Some researchers cite a connection between
command hallucinations and various forms of violence,
whereas others find no empirical evidence of a relation-
ship. Even in the midst of this uncertainty, there are sev-
eral points upon which many studies agree: (a) that the
rates of occurrence for command hallucinations is high
[145], (b) that such symptoms are vastly underreported
[146], and (c) that command hallucinations hold clinical
significance for violence even in the absence of statistical
significance [28,142,144].
These conflicting research findings are probably the result
of the methodological problems inherent in this type of
research: underreporting of the symptoms [28,146].,
small sample sizes [3,121], and a lack of standardization
in defining suicidal behavior or the presence of hallucina-
tions. Specifically, the type of hallucination has not
always been clearly stated in the studies, leaving readers
unclear about whether patients were experiencing violent,
suicidal, or benign command hallucinations. Research
also faces the problem of knowing whether patients were
actively hallucinating during the behavior being studied
(suicidal or violent behavior) [147]. Furthermore,
researchers in the past have sampled diagnostically heter-
ogeneous groups, mixing schizophrenia with bipolar dis-
orders, personality disorders, and severe mood disorders
[143-145] These results have then been compared, per-
haps unfairly, to studies that sampled only people with
schizophrenia [143,148,149]
Thus, command hallucinations occur more frequently
than is often recognized and hold potentially vital clinical
significance. In order to prevent suicide, direct screening
for command hallucinations should be incorporated into
any suicide assessment within this patient population.
e. Comorbid substance use disorders
Substance use/abuse/dependence is often comorbid with
schizophrenia, and psychosis and substance use are both
found to increase suicide risk [150]. Researchers, in stud-
ies of two American cohorts, found significantly more
comorbid substance abuse among people with schizo-
phrenia who were suicidal, particularly among the
younger ones [151-153]. They stated that it is important,
in view of the changing patterns in the epidemiology of
schizophrenia comorbid with substance use/abuse, that
clinicians obtain accurate drug-use history in order to
detect and promptly treat drug use/abuse. Youths who
abuse drugs are at increased risk for committing suicide,
and drug or alcohol abuse is found in about 70% of chil-
dren and adolescents who commit suicide [154].
Harris and Barraclough's [10] meta-analysis on suicide as
outcome in mental disorders reported on the standard-
ized mortality ratio (SMR) for various psychoactive sub-
stance-use disorders. After combining the studies, they
compared suicide risks of drug users and nonusers and
found the SMRs for suicide of users to be higher than
those of nonusers in all groups. In subjects with alcohol
dependence and abuse it was 6-times higher, in opioid
dependence and abuse 14-times, and in cannabis users 4-
times. In this meta-analysis, suicide risk among schizo-
phrenic patients was 8.5 times greater than among non-
schizophrenics. Subsequently, Wilcox et al. [155] located
twenty studies not included in the Harris and Barraclough
[10] review and identified another 22 studies published
after 1997. By combining data from all of these studies,
they found more robust associations between suicide and
overall opioid use disorder, mixed intravenous drug use,
alcohol use disorders among women.
The increased suicide risk in substance-abusing schizo-
phrenic patients [156-162] could be the result of a cumu-
lative effect of many factors or events, such as the loss of
remaining social control through the consumption of psy-
chotropic substances, noncompliance with antipsychotic
medication, and presence of paranoia and depression
[163]. In Allebeck and Allgulander's [164] sample of
young male substance abusers, the diagnostic category
associated with the highest suicide risk was schizophrenic
psychosis. Abuse substances worsen both symptoms and
prognosis of the illness and are related to higher relapse
rates.
Suicide may become the ultimate solution for reducing
suffering caused by hopelessness and social isolation. Var-
ious studies have recognized the importance of substance
abuse in the suicides of patients with schizophrenia [165-
169]. Drug and alcohol abuse increase the risk of suicide
in the general population [151,170-173] and, when this
behavior is associated with a diagnosis of schizophrenia,
the risk is much higher. It is also important to take into
consideration the difficulties in reaching marginalized
individuals. A comparison of patients who began drug
abuse before their first admission with those who began
abusing drugs after their first admission showed that the
use of specific drugs was associated with significant differ-
ences in age, age at first hospitalization, premorbid func-
tioning and subtype of schizophrenia. The differences
were not uniform across the different drugs [174].
But, when comparing schizophrenics who attempt suicide
with nonattempters, drug abuse is not found to differ
between the two groups [69]. However, schizophrenic
patients who use substances do have more positive symp-
toms, especially hallucinations [175], and more suicide
attempts than patients with the same diagnosis and noAnnals of General Psychiatry 2007, 6:10 http://www.annals-general-psychiatry.com/content/6/1/10
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substance use [175,176]. Interestingly, hallucinations
[142], but not delusions [177], were found to increase the
incidence of suicide attempts in patients with schizophre-
nia, independently from alcohol/drug abuse/dependence
[142].
f. Suicide risk during adolescence
The suicide risk for adolescents or young adults with
schizophrenia is three times higher than that for adult
schizophrenic patients. The first two years of the disease
are especially dangerous. Suicidality in this group of
young patients often goes along with the harmful use of
psychotropic substances and affective syndromes [178].
Among patients with psychotic symptoms, the risk of sui-
cidal behavior is significant higher in cohorts that include
adolescents and young adults as well as older paitents.
The situation of individuals with first-episode schizophre-
nia in life is often much more unstable since they are not
used to the disorder and since, as adolescents, they are fac-
ing the typical problems and conflicts of young persons
beginning a new phase in life. They are confronted with a
painful psychological crisis with two aspects, and the
symptoms of psychosis might be only a part of this crisis.
In addition other syndromes, such as mood disorders and
addictive behaviors, complicate the situation and increase
the risks for the individual.
Though various approaches for first-episode schizophre-
nia have been developed in recent years, it is still difficult
for a person suffering from symptoms of psychosis for the
first time to find appropriate support. It usually takes sev-
eral months until this person is diagnosed correctly and
treated by a psychiatrist. The current health-care system
still fails to meet the needs of this group of patients. Early
detection and intervention programs are crucial, and sui-
cide prevention must be an important component of
these programs.
g. Suicide risk during hospitalization
A recent Danish register-based study by Qin and Norden-
toft [179] found that 37% of men and 57% of women
who committed suicide had a history of admission to psy-
chiatric hospitals. This suggests that men at risk for suicide
are less likely to seek or receive psychiatric treatment, but
the study confirms previous reports that suicide risk is
highly associated with a history of admission to psychiat-
ric hospital. It further showed that the risk peaked, not
only shortly after discharge as reported in the literature
[180-184], but also shortly after admission. For patients
with schizophrenia and related disorders, there was, as in
other conditions, two sharp peaks in suicide risk, the first
immediately after admission (adjusted risk ratio around
80 compared with persons with no history of admission)
and the second peak shortly after discharge (adjusted risk
ratio around 110 compared with persons with no history
of admission). Approximately one third of the suicides in
schizophrenics occur during admission or during the first
week after discharge. From a preventive perspective, this is
actually good because it identifies important risk periods
upon which preventive interventions should focus. For
instance, suicide among patients with schizophrenia cur-
rently admitted or discharged within last week accounts
for almost three percent of all suicides in Denmark.
It is possible that a very small proportion of the suicides
registered as suicides after discharge were actually suicides
committed while hospitalized if the person did not die
immediately but was transferred to medical department
where he or she died of the consequences of a suicide
attempt carried out during psychiatric hospitalization.
This concerns very few cases and does not influence the
result of the analyses.
What are the time trends in suicide risk associated with 
schizophrenia?
Several papers have reported increasing risk of suicide in
schizophrenia over time [185-187]. This development has
been attributed to deinstitutionalization. To examine this
development carefully in the Danish population,
Mortensen and his colleagues [188,189] combined four
longitudinal population-based registers and followed the
changes in the suicide rates for patients with schizophre-
nia and related disorders. In 1980, the suicide rate of the
general population in Denmark peaked and reached a
level that was among the highest in the world, with 34 sui-
cides per 100,000 inhabitants. After 1980, the number of
suicides decreased each year, and in 1997, the rate was 15
per 100,000 inhabitants, a 56-percent reduction in the
suicide rate during the period 1980–1997. In Denmark,
approximately half of the persons who die from suicide
have previously been admitted to psychiatric departments
and more than one-fourth have been admitted during the
last year [188,189]. The study investigated whether there
was a decline in suicide rate among patients with schizo-
phrenia and related disorders parallel to the decline in the
Danish suicide rate from 1981 to 1997. Although the risk
of suicide among patients with schizophrenia and related
disorders is roughly 20 times higher than among never-
admitted persons in the general population, the suicide
rate among patients with schizophrenia and related disor-
ders in Denmark declined by a half from 1981 to 1997.
The change in the suicide rate among these patients was
the same as the change among never-admitted persons in
the general population, except that patients with non-
schizophrenic psychoses in the schizophrenia spectrum
had a faster decrease in suicide rate compared to the
never-admitted population [190]. Thus, these data did
not support the notion that deinstitutionalization in Den-Annals of General Psychiatry 2007, 6:10 http://www.annals-general-psychiatry.com/content/6/1/10
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mark resulted in an increased suicide rate. It is unknown
whether this finding can be replicated in other countries.
h. Medical staff and suicide risk
The situation of people immediately prior to their suicidal
act is critical for its prevention. Schizophrenic patients
who decide to commit suicide often contact health-care
workers in the days or weeks before their act. However,
many factors impair the ability of treatment professionals
to recognize the acute risk of suicide in their patients.
These factors are related to the suicide phenomenon itself,
to problems associated with the treatment system and to
the treatment practices adopted by professionals, but they
are also related to the personal psychological issues of the
workers [25,191,192].
Staff knowledge of suicidology and their psychological
readiness to deal with the anxiety and despair of suicidal
patients are important in the treatment process, and
uncertainties may be fatal [193]. Increased attention to
interpersonal behaviour may provide a basis for more
accurate recognition and more successful long-term treat-
ment of high-risk suicidal patients. Withdrawal by a
depressed schizophrenic patient and an increase in para-
noid behavior should be regarded as signals of an acutely
increased risk of suicide [25]. In addition, awareness that
psychological and somatic symptoms are connected could
facilitate the identification of an acute risk of suicide
[194].
Particular attention should be paid to the suicide risk in
situations in which the treatment regimen is changed in
some significant way [25,52,53,191,195-202]. Difficulty
in recognizing depression in schizophrenics is further
complicated by the fact that depressive withdrawal from
personal relationships may be misinterpreted as a nega-
tive symptom related to the primary illness [203,204].
Organizational factors and staff turnover are also obsta-
cles to maintaining suicide-prevention activities and mak-
ing them routine in psychiatric care [205].
Interactional factors
Suicide often comes as a surprise to both relatives of the
suicide victim and those who have treated the individual,
even in cases in which the victim was known to be
strongly self-destructive. The feeling of concern evoked by
self-destructive persons in those with whom they are in
contact disappears or is absent immediately prior to sui-
cide. According to Tähkä [206], this is because, after the
final decision to commit suicide, the person ceases to send
emotional messages. When the person no longer hates
anybody but himself, then someone's love and concern
no longer prevents him. The narcissistic regression has
reached a point at which the person has lost his object-ori-
entedness. Loss of concern by professionals is also associ-
ated with an acute risk of suicide in depressed
schizophrenics [25].
Maltsberger [207] has noted that severely self-destructive
persons cannot be reached by means of empathy immedi-
ately before they commit suicide. Calming before suicide
is achieved because formulating suicide plan in itself is
sometimes sufficient to master the sense of intolerable
helplessness [208]. Ringel [209] has described a self-
destructive state using the phrase "ominous quie." In this
situation, the dynamic force expresses the hidden chan-
nelling of the drives into a single direction – negation of
life and self-destruction. Before complete isolation and
the constriction of human relations, there is a period of
dependency on one person only [209] – the chosen res-
cuer [210]. According to Menninger [211], there are three
components in the suicidal act: the wish to kill, the wish
to be killed, and the wish to die. Jensen and Petty [210]
suggest a fourth element – an unfulfilled wish to be res-
cued. In psychotic states, the choice of rescuer can be con-
fused, and then the opportunity for rescue may be brief. It
can also be so symbolic that the fantasy of the suicidal per-
son is imperceptible.
Ignoring the suicide risk is very common in health care
professionals. Knowledge about self-destructiveness in a
patient can even be repressed or denied by an experienced
therapist [190]. Fear of stigmatization because of the
schizophrenia and even more so because of the suicidal
ideation is probably one reason that these clinical ante-
cedents are hidden by the patient and ignored by the ther-
apist. It is important that suicide is one of the topics
discussed regularly during the treatment.
Some depressed schizophrenics, before committing sui-
cide, complain about the treatment personnel and about
their treatment in general. Meissner [213] has described
the relationship between paranoid states and depression,
emphasizing that those who have paranoid ideas often
also have self-destructive ideas. One study has shown that
paranoid ideas are a specific risk factor for suicide in psy-
chotic patients [214]. The same association has also been
found in the case of schizophrenia [26]. In "Practice
guideline for the treatment of patients with schizophre-
nia" [215], it has been pointed out that some risk factors
for suicide in schizophrenia are the same as those for the
general population, and some are specific for schizophre-
nia. These specific factors include severe depressive and
psychotic symptoms, with an increase in the patient's par-
anoid behavior. Accusations against personnel can be
most intense immediately prior to suicide. However, at
the critical moment, just before committing suicide, the
patients cease complaining about staff. The role of para-
noid delusions and projection as factors in increasing the
risk for suicide is not always understood, but understand-Annals of General Psychiatry 2007, 6:10 http://www.annals-general-psychiatry.com/content/6/1/10
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ing their role provides opportunities for preventing sui-
cide [25]. However, the aggression and projective defence
strategies against self-destructiveness in patients are hard
for even experienced professionals to tolerate.
An increase in somatic complaints may also be a sign of
acute suicide risk in schizophrenia as well as in depression
[194,216]. This complaining seems to represent the last
attempt to establish an emotionally meaningful relation-
ship with a care provider immediately before suicide. If a
worker has identified the possibility of depression under-
lying the somatic symptoms but has not talked about it to
the patient, he or she may not have an experience of psy-
chologically important caring during the treatment rela-
tionship.
Postvention
Postsuicide prevention (postvention) should become an
established treatment practice in the cases of patient sui-
cide during health care. Postvention after the patient's sui-
cide is an important part of the treatment relationship and
of the prevention of suicide in other patients. Suicide risk
assessment is the most difficult kind of assessment in psy-
chiatric practice [193,217,218]. Furthermore, treatment
professionals often seem to have great difficulties in rec-
ognizing and dealing with their own affective reactions
and internal incentives [25,191,192]. Specific training
and consultation in suicidology is needed, and it should
address facts and provide skills for dealing with difficult
emotions aroused in the encounter with suicidal patients
A feeling of guilt after a patient's suicide is common
among treatment professionals. However, many survivors
respond well to the concept that their feelings of guilt rep-
resent positive caring for others more than any real culpa-
bility [219]. A patient's suicide is among the most difficult
professional experiences encountered by a psychiatrist
[220]. Adequate supervision, debriefing and postvention
should be provided [25,191,221].
2. Prevention and treatment of suicide in schizophrenia
a. Pharmacotherapy of Suicide in Schizophrenia: The Clozapine 
Indication
There is little evidence that the typical neuroleptic drugs,
with or without antidepressants, as well as the atypical
antipsychotic drugs other than clozapine, have an effect
on fatal or non-fatal suicidal behavior in patients with
schizophrenia [222,223]. However, there is considerable
data that indicates that clozapine does reduce the risk of
suicide. Clozapine was first reported to reduce the rate of
suicidality in 88 patients with schizophrenia in a mirror-
image study [224]. The percentage of patients with no sui-
cidality increased from 53% at baseline to 88% during
treatment with clozapine. There was an 86% decrease in
suicide attempts. Nearly identical results were obtained in
another mirror-image study in hospitalized patients
[225].
An epidemiologic study of mortality and morbidity in
current and former clozapine users based upon the US
Clozaril® National Registry reported that mortality from
suicide was markedly decreased in current clozapine users
in comparison with past users [226]. American and Eng-
lish clozapine registry data revealed a reduced risk of sui-
cide for patients treated with clozapine compared to the
general population of patients with schizophrenia
[227,228].
However, there are limitations in these studies that limit
the confidence that the findings reach the highest stand-
ards of evidence-based medicine, such as no randomiza-
tion of the patients in the treatment groups and the use of
retrospective, broad inclusion criteria. These issues were
addressed in the International Suicide Prevention Trial
(InterSePT), a randomized, two year, open-label trial with
blind ratings, and determination of whether potential
endpoints met criteria for a suicide attempt or a hospital-
ization to prevent suicide by a blind, independent, expert
Suicide Monitoring Board (SMB; Meltzer et al. [61,229]. It
included 980 patients with schizophrenia or schizoaffec-
tive disorder who were at high risk for a subsequent sui-
cide attempt, based primarily on having made at least one
suicide attempt in the three years prior to study entry or
on being currently suicidal. The primary outcome meas-
ure was either time to a suicide attempt (including death
by suicide) or hospitalization to prevent suicide. A signif-
icant 24% difference in the hazard ratio for this endpoint
in favor of clozapine was found. The number of patients
needed to be treated with clozapine in order to reduce the
risk of one suicide event was 13. Clozapine was superior
to olanzapine in patients with schizophrenia or schizoaf-
fective disorder, in neuroleptic-resistant as well as neu-
roleptic responsive patients, and in both males and
females. The two drugs did not differ in overall efficacy in
reducing total psychopathology, positive and negative
symptoms, or depression. Thus, the difference between
the impact of the drugs on suicidality was not secondary
to other efficacy differences, confirming the view of sui-
cide as a separate dimension of the schizophrenia syn-
drome. As a result of this study, the Food and Drug
Administration of the United States approved an indica-
tion for clozapine to reduce the risk of suicide in schizo-
phrenia. Hennen and Baldessarini [230] recently
completed a meta-analysis of available data on the issue
and concluded there was a substantially lower overall risk
of suicidal behavors and completed suicides for clozap-
ine. Thus, there is strong evidence to suggest that, for
patients with schizophrenia or schizoaffective disorder
who have made and survived a serious suicide attempt, or
who can be judged to be at very high risk for such anAnnals of General Psychiatry 2007, 6:10 http://www.annals-general-psychiatry.com/content/6/1/10
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attempt based on careful assessment, clozapine treatment
should be instituted and maintained.
b. Non-Pharmacological Treatment of Suicide in Schizophrenia
Draket al. [201] noted that there is a need for empathic
support in reducing suicide risk. These authors suggested
that clinicians should acknowledge the patient's despair,
discuss losses and daily difficulties, and help to establish
new and accessible goals. Social isolation and work
impairment have been reported as risk factors for suicide
in individuals with schizophrenia [27,53,231]. Individu-
als with good premorbid functioning are those more at
risk of suicide. Interventions such as social skills training,
vocational rehabilitation and supportive employment are
therefore very important in the prevention of suicide in
schizophrenic patients. Broadly speaking, these kinds of
therapies focus on working out daily problems rather than
achieving psychological insight. It has become increas-
ingly clear that supportive, reality-orientated therapies are
generally of great value in the treatment of patients with
schizophrenia. In particular, supportive psychotherapy
aims at offering the patient the opportunity to meet with
the therapist and discuss the difficulties encountered in
daily activities. Patients are encouraged to discuss con-
cerns about medications and side-effects as well as issues
such as social isolation, money and stigma. The therapist
plays an active role as he gives suggestions and shares
good and bad periods empathically. The nature of these
treatments and their availability vary greatly from place to
place. Psychosocial approaches have however limited
value for acutely psychotic patients.
Mueser and Berenbaum [232] reviewed controlled trials
of psychotherapy and concluded that reality-orientated
psychotherapy is superior to a dynamic, insight-orien-
tated approach. Nevertheless, exploratory psychotherapy
may have some benefits as it gives patients who have
achieved stable remission the opportunity to understand
inner conflicts and discuss, within a solid therapeutic alli-
ance, suicidal thoughts or suicidal behavior. Patients learn
to dealuse symbolism and thought rather than action
(suicide) [233,234]. However, any psychotherapy tech-
nique with schizophrenic patients requires certain altera-
tion and modifications of the standard approach [235-
237]. An approach elaborated by Hogarty et al. [238,239]
is Personal Therapy, which includes three levels of treat-
ment with defined criteria for progression from basic to
more challenging levels. Treatment begins from early
months after discharge, which aims at clinical stabiliza-
tion and therapeutic joining, and moves in later phases to
promoting introspection and an understanding of the
relationship between stressors and maladaptive
responses. An intermediate phase promotes skills remedi-
ation, relaxation training, role-playing and psychoeduca-
tion. There is evidence to suggest that the combination of
psychosocial and pharmacological treatments increases
compliance and helps to achieve a better outcome [240].
Cotton et al. [53] stressed the importance of psychother-
apy with schizophrenic patients who are at risk of suicide
and noted the need to appreciate their hopeless awareness
of the chronic illness. According to Westermeyer et al [64],
the surviving schizophrenic individual may be the type of
patient who is able to adjust to life as a chronic schizo-
phrenic or as a moderately and episodically impaired
schizophrenic, and thus may be less likely to commit sui-
cide.
Increased insight may parallel increased suicidality, but
this is not per se a reason to try to decrease insight in
patients with schizophrenia. In fact, insight is also posi-
tively related to compliance with treatment, both medica-
tion and psychotherapy, which both can help to reduce
suicidality. Gradual increases in insight secondary to treat-
ment were also related to decreased suicidality in one
study. Dramatic increases in insight should, however, be
avoided and should be managed within an appropriate
therapeutic relationship. Structured psychotherapies
might add to the benefits of successful drug treatment of
schizophrenic patients. Thus, insight may have a bidirec-
tional impact on suicidality. It might increase it through
increased hopelessness and despair [241], and these feel-
ings may arise because the patient realizes that he or she
with have to depend on lifelong medication and/or
understands the social consequences of having schizo-
phrenia. On the other hand, gradual gains in insight
brought about by successful drug treatment and/or psy-
chotherapy may decrease suicidality and may further con-
tribute to compliance, which is a factor that protects the
patients from relapses and recurrences. In turn, the benefit
from adhering to treatment may make the patient's out-
look on his or her illness more positive, thereby reducing
suicidality. The best way to achieve these goals may be to
combine drug treatment with psychotherapy, a method
that has proved to be superior to each type of treatment
alone in other types of mental disorders. Controlled data
in this respect, however, are lacking [82].
c. Changes in suicide rates
The suicide rate expresses a balance between protective
and risk factors. During the last century, several measures
might have influenced the suicide rate. The introduction
of chlorpromazine in the 1950s made it possible to treat
the psychotic symptoms of schizophrenia but, in the years
after the introduction of chlorpromazine, the suicide rate
actually increased. This might have resulted from
increased patient insight into the illness. The patients
were not racked with hallucinations or delusions, but they
were still not capable of working or living without help
from the community [242].Annals of General Psychiatry 2007, 6:10 http://www.annals-general-psychiatry.com/content/6/1/10
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Deinstitutionalization began in the 1960s, and the
number of hospital beds decreased during the following
40 years. However, the association between these changes
and the suicide rate is not clear. The intent of deinstitu-
tionalization was to improve the quality of life for
patients, but it is a very difficult and demanding challenge
for the society to treat patients with schizophrenia in their
homes. It is not accomplished simply by closing beds. The
influence of deinstitutionalization on the suicide rate is
difficult to interpret because there were conflicting results
[186,243,244]. The number of beds also produced con-
flicting results because many patients were actually not
discharged to their homes but to other institutions. Thus,
a trans-institutionalization occurred in many cases.
In the 1990s, the atypical antipsychotics were introduced
and it seems that these drugs might have some anti-sui-
cidal properties, especially clozapine [230,245]. This
might be to due their lesser propensity to cause extra
pyramidal side-effects (EPS). (There is some evidence for
a relationship between suicidality and EPS [95].
Another factor influencing the suicide rate could be the
introduction of the selective serotonin reuptake inhibitors
(SSRI) in the 1980s because they are less toxic in overdose
and because it now became easier to treat depression in
patients with schizophrenia. Depression in schizophrenia
is very common and is associated with suicidality [8,246].
According to the WHO, the general worldwide suicide rate
has increased the last 50 years. The figures for suicide in
schizophrenia are not present for many countries, but in
Denmark and Norway the suicide rate in schizophrenia
has been decreasing since 1990 (Gurli Perto, Danish Cen-
tral Psychiatric Research Register, personal communica-
tion 2005 and Statistics Norway), paralleling canges in the
general suicide rate.
IV. Conclusions: Preventive Measures and Goals 
for the Future
The clinical implications of this review are that prevention
is likely to result from active treatment of affective symp-
toms and syndromes, improving adherence to medica-
tions, and maintaining special vigilance in patients with
risk factors [30]. Clinical practice guidelines have identi-
fied a number of evidence-based treatments related to
reducing suicidality in schizophrenia [220].
Difficulties in assessing suicidal risk in schizophrenia are
related to the phenomenon of suicide per se, to problems
associated with the treatment system or treatment prac-
tices, and to the personal psychological issues of the work-
ers. Suicidal acts among people with schizophrenia were
reported as being often so impulsive and difficult to pre-
dict that the traditional risk scales and interviews were of
limited value in a clinical assessment [247]. However,
schizophrenics do communicate their potential for sui-
cide [248]. The American Psychiatric Association's clinical
practice guidelines for assessment and treatment of
patients with suicidal behaviors have provided an outline
and clinical details for assessing individual patients [220].
An important issue for further investigate and understand
suicide in schizophrenia is family history of suicide. Such
topic was investigated in several studies and results were
conflicting. In a metaanalysis, Hawton[30]found that
family history of suicide among patients with schizophre-
nia was associated with OR = 1.82, (95 % CI = 0.56–5.94),
thus a non-significant finding. Roy [249] inestigated 243
patients with a family history of suicide who were com-
pared with 5,602 patients with no family history of sui-
cide. A family history of suicide was found to significantly
increase the risk for an attempt at suicide in patients with
a wide variety of diagnoses: schizophrenia, unipolar and
bipolar affective disorders, depressive neurosis, and per-
sonality disorders.
The data linking positive and negative symptoms to later
suicidal activity suggest a diagnosis-specific model for
some risk factors. Positive symptoms may be suicide risk
factors for some diagnostic groups and negative symp-
toms for other diagnostic groups, while poor functioning
may be a general diagnoistic-free suicide risk factor.
Mann et al. [250] reviewed the literature and identified a
number of strategies that are effective in the prevention of
suicide such as education and awareness programs for the
general public, primary care providers and other gatekeep-
ers, screening for individuals at high risk, and providing
treatment using pharmacotherapy and psychotherapy. In
particular, the prevention of suicide in schizophrenia
should include providing proper information for the fam-
ily members of the patient in the hope of reducing their
hostility toward the patient. In addition, continuity of
care after suicide attempts, restricting access to lethal
methods and media reporting guidelines are important
strategies to prevent suicide. Since it is such a strong pre-
dictor of future suicide, preventing and reducing
attempted suicide in schizophrenia may have a positive
long-term impact.
Pompili et al. [251,252] reviewed the literature that dealt
with the nursing of schizophrenic patients who are at risk
of suicide These authors outlined key problems encoun-
tered in the nursing of these individuals, such as the
unpredictability of suicide due to their fluctuating suicidal
ideation, the staff's "countertransference" reactions to
these patients, and the apparent improvement that pre-
cedes suicides. Nursing a schizophrenic patient who is at
risk of suicide involves the establishment of a very uniqueAnnals of General Psychiatry 2007, 6:10 http://www.annals-general-psychiatry.com/content/6/1/10
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relationship. Furthermore, the physicians' role in the pre-
diction, prevention and management of suicide risk
among schizophrenic patients should not be underesti-
mated [253,254]. Family members are stigmatized for
dealing with schizophrenia. This psychiatric disorder
often results in impairment of daily activities, relapses and
chronicity. Family members are viewed with suspicion as
they cope with their sick relative, and they may be sub-
jected to fewer social activities and reduced job opportu-
nities. The family's difficulties and perceived
stigmatization have been reported as possible contribut-
ing factors to the suicide of schizophrenic patients [255].
Finally, treatment professionals, as well as family mem-
bers and other bereaved survivers of suicide, need encour-
agement to grieve and express their feelings about the
suicide victim.
Pompili et al. [82] have recently stressed the need to
implement prevention programs for suicide among schiz-
ophrenic patients. These authors focused on primary, sec-
ondary and tertiary prevention. Primary prevention
represents the search for the prevention and the elimina-
tion of risk factors. These factors include social isolation,
substance abuse, depression, hopelessness and disap-
pointment for lost expectations for the future. Insight into
the illness should be monitored very carefully as it has
become apparent that the awareness of one's illness leads
to discouragement and increased suicide risk. Appropriate
pharmacotherapy and psychotherapy should prevent the
emergence of risk factors for suicide and the reduction of
those factors already detected in the patient. Patients
should always be asked about their intention to commit
suicide. There are no contraindications to the direct inves-
tigation of suicidality in schizophrenic patients. They are
instead relieved by an explicit investigation as they have
the opportunity to share their inner feelings [256].
Secondary prevention aims to check the phenomena in
those subjects who have already developed risk factors for
suicide. State-dependent risk factors are those that can
potentially be modified (such as depression, substance
abuse and hopelessness), while trait-dependent risk fac-
tors are unchangeable (such as gender, age and premorbid
functioning). No doubt, a prompt recognition of individ-
uals who are at risk is a key element in the prevention of
suicide. Screening procedures taking into account suicidal
indicators should be implemented. Patients who are
depressed, substance abusers and hopeless should be
monitored carefully. Those who have experienced multi-
ple hospitalizations and previously threatened or
attempted suicide should be treated with adequate proce-
dures, such as programs of aftercare and psychosocial
intervention.
Tertiary prevention is addressed to those individuals who
have attempted suicide or have been suicidal in the past.
Destigmatisation should be addressed to mental illness as
well as suicide. Increasing the stigma associated with hav-
ing suicidal feelings will increase the suicide rate. Inter-
ventions among families, mental health professionals and
church activists aimed at decreasing the stigma associated
with mental illness and suicide may contribute to the
reduction of deaths by suicide. Pharmacological interven-
tions are no doubt of paramount importance, but psycho-
social interventions and psychoatherapy also play a
central role.
This review has several limitations. It does not present
mata-analytic results, and the authors adopted a narrative
approach in order to summarise the information regard-
ing suicide in schizophrenia. However, contributions
were provided by scholars with an international reputa-
tion in this field. For this reason, this review differs from
previous reviews and represents an original consensus
conference approach from many authors who provided,
on the basis of their expertise, a brief essay on specific
aspects of the problem. References selected for this study
may not include all of the works dedicated to the topic.
Other key works may be available and may provide fur-
ther understanding of the topic. Clearly, more joint efforts
of this kind are needed to develop sound, shared guide-
lines for the prevention of suicide among individuals
affected by schizophrenia.
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